THE INVESTMENT COLUMN: Elan tries to put the past behind it
Wednesday 09 February 2005
It had essentially mortgaged its biotech investments, and when they collapsed in value, Elan came to the brink of bankruptcy. New management had to ensure a piece-by-piece unpicking of those collaborations, a massive fire-sale of assets, and the $85m (pounds 46m) settlement of investor lawsuits which alleged that Elan misled the market.
Yesterday, a last piece of the jigsaw was in place with the agreement of a $15m settlement with the US regulator, the Securities and Exchange Commission.
So what is Elan now? It has sales from prescription jabs Azactam and Maxipime for pneumonia and other infections, and income from contract manufacturing for other drug companies. But it is three new products which ought to drive growth at the company. Tysabri is a new treatment for multiple sclerosis, developed in collaboration with Biogen Idec of the US, and take-up has been strong since the drug's launch in November. Some analysts expect it to have sales of $3bn a year when it becomes well-established. It could also be extended for use in rheumatoid arthritis.
A second drug, Prialt, for chronic pain, was also launched last year. And then there is work on Elan's potential new Alzheimer's disease drug, which has suffered setbacks but could come to fruition around the end of the decade.
At the company's full-year results yesterday, Elan reiterated its confidence in returning to profit by the end of 2006. There was a warning of higher costs than the market had expected, but generally the results helped in the process of restoring confidence. Hold.
- 1 Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
- 2 Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
- 3 The Simpsons death: Creator Al Jean would 'kill himself' before character like Homer or Lisa
- 4 British man raped while urinating in bushes at Oktoberfest beer festival in Germany
- 5 A teacher speaks out: 'I'm effectively being forced out of a career that I wanted to love'
Five-year-old Iris Grace is raising awareness of autism through her extraordinary paintings
Car tax disc changes: Two days to go - and they affect you much more than just not displaying a piece of paper
Isis an hour away from Baghdad - with no sign of Iraq army being able to make a successful counter-attack
British man raped while urinating in bushes at Oktoberfest beer festival in Germany
George Clooney and Amal Alamuddin wedding: The famous congratulate actor and human rights lawyer after Venice nuptials
Isis, we are told, is a 'clear and dangerous threat to our way of life'. I’m sorry, but I just don’t buy it
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
'Women, walk wherever you want' posters taken down in Stamford Hill following 'unacceptable' signs separating men and women
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Mark Reckless becomes second Tory MP to defect to Ukip in a month
Should gay sex be illegal? 16% of Britons think so
- < Previous
- Next >
iJobs Money & Business
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...
£300 - £330 per day: Ashdown Group: SQL Developer (Stored Procedures) Watford...